4//SEC Filing
KKR Management Holdings L.P. 4
Accession 0001140361-20-000250
CIK 0001743881other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 6:08 PM ET
Size
12.4 KB
Accession
0001140361-20-000250
Insider Transaction Report
Form 4
KKR Management Holdings L.P.
10% Owner
Transactions
- Other
Common Stock
2020-01-01−36,900,661→ 0 total(indirect: See footnotes)
KKR Management Holdings Corp
10% Owner
Transactions
- Other
Common Stock
2020-01-01−36,900,661→ 0 total(indirect: See footnotes)
Footnotes (3)
- [F1]Pursuant to an internal reorganization, on January 1, 2020 KKR Management Holdings Corp. was merged into its parent, KKR Group Holdings Corp., and KKR Management Holdings L.P. was merged into KKR Fund Holdings L.P., an existing subsidiary of KKR & Co. Inc. KKR Fund Holdings L.P. was then renamed KKR Group Partnership L.P. As a result, KKR Management Holdings Corp. and KKR Management Holdings L.P. ceased to exist as separate entities. KKR Management Holdings Corp. and KKR Management Holdings L.P. are filing this exit Form 4 to report that they are no longer beneficial owners of securities of BridgeBio Pharma, Inc. (the "Issuer"). KKR Group Partnership L.P. is separately filing a Form 3 to report beneficial ownership of Issuer securities in connection with the above reorganization. This internal reorganization did not involve any purchase or sale of securities of the Issuer.
- [F2]The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
- [F3]Each of the Reporting Persons may have been deemed to be the beneficial owner of all or a portion of the securities reported herein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Persons engaged in any transactions subject to Section 16 of the Securities Exchange Act of 1934 or are or were the beneficial owners of any securities reported herein, and the Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001472693
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 6:08 PM ET
- Size
- 12.4 KB